MARKET OUTLOOK
The lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novartis) and Verzenios (Eli Lilly) are creating new dynamics in the treatment of metastatic disease, while PARP inhibitor Lynparza (AstraZeneca) is poised to offer treatment for BRCA1/2-mutation-positive tumors. In addition, near-term emerging agents including PI3K inhibitor alpelisib (Novartis), look set to further strengthen the field. This research examines the market access levers and barriers for existing and emerging HR-positive, HER2-negative breast cancer therapies in the top 5 European markets (France, Germany, Italy, Spain, UK) as competition intensifies, the reimbursement environment becomes ever more complex, and healthcare budgets become increasingly constrained.
QUESTIONS ANSWERED
- What role do key brands play in HR-positive, HER2-negative breast cancer treatment in the markets under study? How is their use monitored and restricted?
- How great an uptake advantage is CDK4/6 inhibitor Ibrance’s first-to-market status? What market access strategies help Kisqali and Verzenios to compete?
- Which treatments do surveyed oncologists think perform best on clinical and other attributes? Do interviewed payers consider the overall cost of biomarker-driven prescribing to be justified?
- How can emerging HR+/HER2- breast cancer therapies optimize reimbursement and market access in the top European markets.
PRODUCT DESCRIPTION
European Access & Reimbursement provides integrated brand-level and country-specific analysis of primary market research conducted with payers and prescribers, examining reimbursement dynamics and evaluating the impact of payer policy on prescribing behavior.
GEOGRAPHY
France, Germany, Italy, Spain, United Kingdom
PRIMARY RESEARCH
- Survey of 250 medical oncologists across the top 5 European markets (50 per country)
- Interviews with 10 payers across the top 5 European markets (2 per country)Key Drugs Covered
KEY DRUGS COVERED
Afinitor, Faslodex, Ibrance, Kisgali, Verzenios, Avastin, Anastrozole, Letrozole, Exemestane, Lynparza, alpelisib
CONTENT HIGHLIGHTS
- Actionable recommendations to optimize market access
- Market access success and stumbles
- Market access roadblocks
- Pricing and reimbursement dynamics
- Impact of payer policy and coverage on prescribing
- Market access outlook for emerging therapies
Henrique Duarte
Henrique Duarte is an analyst on the Global Market Access Insights team at DRG, part of Clarivate. He is responsible for monitoring, analyzing, and reporting on global market access through the production of DRG’s Global Market Access Solution (GMAS) and Access & Reimbursement products. His focus is the EU5 and some Latin American countries. He holds a pharmaceutical science degree from the Universidade Lusófona and a postgraduate certificate in health economics from the University of York.
Sonia Alesso
Since joining DRG Abacus as a Medical Writer, Sonia has gained experience across a variety of projects including health technology assessment (HTA) submissions, publication manuscripts, posters, advanced budgetary notification documents, value dossiers and value communications suites. Her disease areas of expertise include schizophrenia, depression, attention deficit hyperactivity disorder (ADHD), haematology, dysphagia and orphan diseases.
Prior to joining DRG Abacus, Sonia was a Senior Medicinal Chemist at a biotechnology company in Oxfordshire. Over the course of her 11-year career as a Medicinal Chemist, Sonia has gained experience writing manuscripts for peer‑reviewed journals and intellectual property documents. Sonia has a Masters of Organic Chemistry from the University of Palermo, Italy, and a PhD from the University of Southampton investigating solid supported reagents for use in combinatorial organic chemistry. Sonia is bilingual (English and Italian).